Cellectis SA earnings date
Cellectis SA (ZVAA) Q3 2026 Earnings Report
DE:ZVAA Q3 2026 EPS Results
- Actual EPS
- -EUR 0.55
- Consensus EPS
- -EUR 0.16
- Beat/Miss
- Missed by -EUR 0.39
- One Year Ago EPS
- EUR 0.01
DE:ZVAA Q3 2026 Revenue Results
- Actual Revenue
- ―
- Expected Revenue
- EUR 14.16M
- Beat/Miss
- ―
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/13/2026
- Time
- Before Open
- Conference Call
- Friday, November 13, 2026
Cellectis SA's next earnings date is estimated for March 4, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call had a predominantly positive tone centered on Cellectis's strategic shift to in vivo gene editing, encouraging HEAL-101 and HEAL-201 preclinical data, clinical timelines, trial preparation, and a projected cash runway into the second half of 2028. The company also reported a substantially improved net financial result. Offsetting factors included the discontinuation of legacy cell therapy programs, a planned workforce reduction of up to 70%, lower revenue, higher transition-related expenses, declining cash balances, and the fact that clinical validation and HEAL-201 LDL-C data remain pending. Overall, the highlights significantly outweighed the lowlights.
Cellectis expects the investigator-initiated HEAL-101 trial in China to start dose escalation in Q1, with preliminary clinical data expected in the second half of 2027; the first cohort is anticipated to have a level of efficacy, and by the end of year the company expects to start seeing the nine-month type of durability of effect. HEAL-201 is planned to be phase I, with preliminary clinical data expected in the first half of 2028, while LDL-C reductions are expected to be disclosed in June. The company expects global headcount to be reduced by up to 70% from its pre-transition level over the course of 2026 and 2027, and, once its realignment is fully implemented as planned, expects to have a cash runway into the second half of 2028.
- Strategic Transformation to In Vivo Gene EditingCellectis has transformed into an in vivo gene editing company focused initially on severe dyslipidemias, with HEAL-101 and HEAL-201 designed as single-injection therapies with the potential for long-lasting effects.
- HEAL-101 APOC3 Editing and Triglyceride ReductionIn a hypertriglyceridemic human APOC3 transgenic mouse model, a single administration of HEAL-101 reduced APOC3 levels by 67% and triglycerides by 76%. Editing reached up to 70% and was detected in the liver, with no significant editing detected in other tissues analyzed.
- HEAL-101 Precision and Liver Safety ProfileIn a human hepatic cell line, HEAL-101 achieved mean APOC3 editing of approximately 90%, with minimal indels, no detectable DNA double-strand breaks at the target site, and no detectable editing at the top putative off-target sites. In a normal lipidemic humanized liver mouse model, mean editing was approximately 65%, with no significant increase in ALT levels compared with untreated controls.
- HEAL-101 Functional Preclinical ResultsThe company reported a consistent progression from gene editing to protein reduction and lipid effects, including lower circulating APOC3 levels and lower triglycerides in a humanized liver mouse model. The company also stated that the expanded dataset included more measurement points and additional dose escalation compared with the September presentation.
- HEAL-101 Clinical Trial TimingThe investigator-initiated HEAL-101 trial in China remains on track, with initiation planned after dose modeling and preparation activities and preliminary clinical data expected in the second half of 2027.
- HEAL-201 PCSK9 Preclinical ResultsHEAL-201 achieved mean on-site epigenetic editing above 90% in human hepatic cell lines, with no off-site changes detected in gene or protein expression. In a humanized liver mouse model, it reduced mean plasma PCSK9 levels by more than 90%.
- HEAL-201 Development PlanBased on the preclinical results, Cellectis is preparing the next step for HEAL-201 as a Phase I program, with preliminary clinical data expected in the first half of 2028.
- Rationale for APOC3 Target SelectionManagement stated that market research among cardiologists, endocrinologists, and internists indicated APOC3 was viewed as superior to ANGPTL3 for specifically targeting triglycerides. The company also cited a clear proof of concept for APOC3 through antisense oligonucleotide and RNA approaches.
- China Trial Expertise and Dose StrategyCellectis has selected the sites for the investigator-initiated trial in China, although it has not yet received agreement to disclose them publicly. The principal investigator was described as a leading treater in the space with extensive gene therapy experience. The company expects dose escalation but plans to use modeling to start at a safe dose that is also expected to be effective.
- LNP Delivery Platform ExperienceThe LNP delivery system is being developed with a biotechnology company whose LNPs have previously been used clinically for liver transduction with RNA and have demonstrated a very good safety profile and high efficiency. Cellectis is also using mouse and non-human-primate modeling to support dose selection, and management described the available liver toxicity data as reassuring.
- Large Addressable Market for HEAL-101Management estimated the target population for HEAL-101 at approximately 1.1 million patients across the U.S. and EU5, or EU4 plus the U.K. The company stated that the potential durability of response could support positioning as a best-in-class product in an established severe hypertriglyceridemia market.
- Potential Pricing and Gross-Margin OpportunityManagement stated that demonstrating durability over years could support higher pricing relative to the annual pricing of current severe hypertriglyceridemia therapies. It also stated that mRNA formulated in LNP has extremely low cost of goods and that the gross-margin potential of these products is substantial.
- Cash Runway Through Key Clinical MilestonesOnce the realignment is fully implemented as planned, Cellectis expects to have a cash runway into the second half of 2028, extending beyond the expected HEAL-101 preliminary data in the second half of 2027 and HEAL-201 preliminary data in the first half of 2028.
- Improved Net Financial ResultFor the nine months ended September 30, 2026, the company reported a consolidated net gain of $5.2 million compared with a net financial loss of $25.6 million in the prior-year period. The $30.8 million improvement reflected a $10.8 million increase in financial income and a $20.0 million decrease in financial expenses.
- Partnership Portfolio Remains a Source of ValueManagement stated that partnerships with AstraZeneca, Servier, Allogene, and Iovance remain an important source of value for Cellectis.
DE:ZVAA Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 04, 2027 | 2026 (Q4) | -0.24- | -0.24 | ― | ― |
| Nov 13, 2026 | 2026 (Q3) | -0.16-0.55 | 0.01 | -6200.00% (-0.56) | |
| Aug 06, 2026 | 2026 (Q2) | -0.24-0.20 | -0.22 | 8.33% (+0.02) | |
| May 11, 2026 | 2026 (Q1) | -0.23-0.16 | -0.16 | 0.00% (+0.00) | |
| Mar 19, 2026 | 2025 (Q4) | -0.18-0.24 | -0.15 | -52.94% (-0.08) | |
| Nov 07, 2025 | 2025 (Q3) | -0.210.01 | -0.21 | 104.35% (+0.22) | |
| Aug 04, 2025 | 2025 (Q2) | -0.19-0.22 | -0.25 | 14.29% (+0.04) | |
| May 12, 2025 | 2025 (Q1) | -0.14-0.16 | 0.07 | -325.00% (-0.24) | |
| Mar 13, 2025 | 2024 (Q4) | -0.17-0.15 | -0.58 | 73.44% (+0.43) | |
| Nov 04, 2024 | 2024 (Q3) | -0.18-0.21 | -0.28 | 25.81% (+0.07) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

